Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells
Key facts
- Who runs it
- Guangdong GD Kongming Biotech LLC
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1/2
- Started
- 1 Nov 2021
- Ended
- 31 Oct 2024
- Type of study
- Interventional
- Treatments tested
- GDKM-100 injection
- Record updated
- 18 January 2023
- Why it stopped
- COVID1-19 pandemic
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (15)Hide the full registry criteria
Who can take part
- Age is 18-75 years old, and gender is unlimited
- HCC was confirmed by pathological or clinical examination
- Patients with stage CNLCIII, IV primary HCC who are receiving second-line treatment / unable to receive existing treatments, or CNLCI and II of primary HCC patients who are unable to receive existing treatments
- Male subjects with partner women of childbearing age must have reliable, effective methods of contraception starting from the signing of the informed consent form until 120 days after the last dose of the study drug. Male subjects with a pregnant spouse must use condoms without other contraceptive methods
- Participants volunteered to join the study, signed an informed consent, had good compliance, and cooperated with the follow-up
Who cannot take part
- Accept other cellular or immune clinical experiments within 8 weeks before enrollment
- Hormone use during cell therapy: dexamethasone dose exceeds 2mg / day during immunotherapy
- Gastrointestinal bleeding, refractory ascites, hepatic encephalopathy, or hepatorenal syndrome
- Immunological deficiency, a known immunosuppressive disease or HIV
- Active infection, unexplained fever
- Serious or unstable heart, lung, kidney and hematopoietic system diseases
- Autoimmune diseases, such as rheumatoid arthritis
- Neurological diseases, diffuse leptomeningeal diseases; combined with neurodegenerative diseases
- The subject had a known history of psychotropic substance abuse or drug use; he had stopped drinking Patients can be enrolled; 11 In the judgment of the investigator, the subject has other factors that may cause the forced termination of the study, such as other serious diseases or serious abnormal laboratory examination or other family or social factors that will affect the subject's safety of the subject, or the collection of trial data and samples
- Pregnant or lactating women
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Brief Summary: In this study, effects of γδ T cells on Advanced hepatocyte carcinoma The goal of this clinical trial is to learn about effects of allogeneic γδ T therapy in advanced hepatocyte carcinoma patients.
Read full original descriptionShow less
The main question it aims to answer is:Will advanced hepatocyte carcinoma patients be benefit from allogeneic γδ T therapy? Participants will received GDKM-100injection (allo-γδ T Cells) Infusion every two weeks.
The group in the trial
- GDKM-100 injectionTreatment being tested
In this trial, the patients will receive multiple high-activity γδ T cell immunotherapies.The trial is divided into two parts: Part 1 is a multiple-dose escalation trial consisting of 3 dose groups (2×10\^8 cells/person, 5×10\^8 cells/person, 10×10\^8 cells/person at 1-3 infusion, 4-6 infusion and 7-9 infusion), with 9 patients planned to be enrolled. Part 2 is a single dose trial in which doctor and the PI evaluates whether to give the rest patients to receive the 10×10\^8 cells/person infusions based on available safety data. The check indexes are CT scan,intestinal flora detection and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Study on Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells
- Record updated
- 18 January 2023